

OCEP

INFORMATION REPORT INFORMATION REPORT

CENTRAL INTELLIGENCE AGENCY

This material contains information affecting the National Defense of the United States within the meaning of the Espionage Laws, Title 18, U.S.C. Secs. 793 and 794, the transmission or revelation of which in any manner to an unauthorized person is prohibited by law.

25X1

S-E-C-R-E-T

COUNTRY East Germany

REPORT

SUBJECT Description of Various Human and Animal Pharmaceuticals

DATE DISTR. 29 January 1957

25X1

NO. PAGES 1

REQUIREMENT NO. RD

REFERENCES

DATE OF INFO.

PLACE & DATE ACQ.

25X1

SOURCE EVALUATIONS ARE DEFINITIVE. APPRAISAL OF CONTENT IS TENTATIVE.

reports (in English) describing various human and animal pharmaceuticals, presumably manufactured by the East German factory name below

25X1

Annex A -- description of "Oestrastilben-D," a 4.4-dimethoxy-1.2-diethylstilben, "for Prostatic Diseases and Other Indications in the Deposit Therapy of Follicle Stimulating Hormones," apparently manufactured by VEB Pharmazeutisches Werk Berlin-Johannisthal. (9 pages in English)

Annex B -- description of vitamin K "Pharma," a 2-methyl-1.4-naphthochinon-sodium bisulphite, apparently manufactured by VEB Pharmazeutisches Werk Berlin-Johannisthal. (6 pages in English)

Annex C -- description of Olypon AFE, an "auxiliary colouring matter for sulphur dyeing" of textiles, apparently manufactured by VEB Chemische Fabrik Gruenau. (4 pages in English)

Annex D -- description of various pharmaceuticals listed in the "Veterinary Drug Catalogue 1956," apparently these preparations are being manufactured by VEB Chemische Fabrik Falkensee. (6 pages in English)

Annex E -- another listing and description of pharmaceuticals from the "Veterinary Drug Catalogue 1956," stating that these preparations are being manufactured as of 1 January 1956 by VEB Chemische Fabrik Falkensee; the report also contains a brief description of conditions for sale and delivery. (6 pages in English)

25X1

S-E-C-R-E-T

25X1

DATE	X ARMY	X NAVY	X AIR	X FBI	AEC				
------	--------	--------	-------	-------	-----	--	--	--	--

Note: Washington distribution indicated by "X"; Field distribution by "#".

INFORMATION REPORT INFORMATION REPORT

ULTRA 3 T L L 2 1 1 1
(Deposit)

General:

118312

In course of the systematic researches concerning the endocrine processes within the organism the hormones have gained, especially during the latest years past, more and more importance for the therapy in the line of various complaints. At the same time, however, also the more particular knowledge of the connections has resulted in refined methodics of the hormone therapy of improved accommodation to given physiological conditions.

The natural work of the gland with its continuous secretion of hormones is faced, in case of endocrine insufficiency, a relatively but short-time and not continuous influence on the endocrine system if simple hormone preparations are given orally or parenterally. Such medication entails, especially upon higher dosages of simple hormone preparations, a sudden and excessive offer of hormones which cannot entirely utilized at once and are partially eliminated again according to the flow over principle. Disregarding the variations in the hormone level caused in this way and deteriorating the therapy conditions, in this connection just the extragenital influences of female sex hormones frequently take disturbing effect. In the event of insignificant biological and pathological deteriorations of hormonal action such influences can be obviated to largest extent by well adapted dosing of the drug; this is not true, however, in case of far-reaching endocrine insufficiency and disturbance of the ovarian function as well as in the event of diseases responding only to prolonged medication of highly dosed follicle stimulating hormones.

Practical medicine, therefore, is looking for the treatment of such diseases, for follicle stimulating hormones drugs securing, according to their deposit-like effect, a balanced hormone level which is maintained for prolonged time, and that without regard to the facilitations offered by the reduced frequency of application of such preparations both to the doctor and to the patient.

In contradistinction to the esterification of oestrogens matters making them staying in the organism, according to their chemical structure, for a more or less prolonged time, and to the utilization of "physical deposits" in shape of implantations and crystal suspensions, the "Oestrastilben D" effects an etherification of a synthetic oestrogen to a so-called "conversion deposit". This term denotes a medical matter chemical structure of which makes it ineffective at the time of application, and which does not take effect within the organism until upon conversion into a medicament attaining the end the therapy is aiming at, and that by splitting off or other biochemical processes. The forced protracting effect is based on the duration of the conversion process.

Chemical:

"OESTRASTILBEN D" is a 4*4-dimethoxy-1*2-diethylstilben. One ampoule of 2 ccm contains 12 milligrams of the biocatalyst dissolved in oleum perum tauri.

It is believed that the injection of the dimethoxydiethylstilben effects a so-called conversion deposit; that means, according to Biogen (7), that the effect of such deposit is to be released secondarily by a slowly proceeding chemical reaction within the body. According to this such dimethyl ether is biologically inactive. Not earlier than within the organism the oestrogen-effective dioxidiethylstilben is set free by gradual splitting off of the two methyl groups, and, streaming slowly into the blood-vessels, it takes long lasting oestrogenous effect. The splitting-off process of the methyl groups is extended, according to the doses applied, to a couple of weeks, thus resulting in an extremely small elimination of the dimethyl ether.

Pharmacological:

The testing of the dimethoxydiethylstilben according to known international units does not permit any comparative utilization against other simple synthetic oestrogens, due to the characteristic mode of effect of this preparation. Small doses of "OESTRASTILBEN D" are able to release a not very impressive oestrus at a gelded female rat, it is true, but such effect could have been attained also by fractions of such doses of simple follicle stimulating hormones. The deposit

effect entailing a rutting season lasting for weeks does not appear until a higher - and varying - dosing threshold is exceeded. By this behaviour of the preparation the splitting-off process proceeding in small partial quantities within a prolonged time may be considered proved. Apart from this animal experiments resulted in completely coincident effects when comparing "OESTRASILBEN D" with other preparations of similar structure.

Local injuries, stimulating effects, or toxic phenomena were not observed when using "OESTRASILBEN D" for animal experiments. The pharmacological test of the preparation has been executed in the Pharmacological Institute of the University at Leipzig under the direction of Prof. Dr. Haenschel. The production of "OESTRASILBEN D" is continuously supervised and controlled by the Institute for Experimental Endocrinology of the Humboldt-University at Berlin under the direction of Prof. Dr. Hohlweg.

Infoming Hints:

"OESTRASILBEN D" is applied by intramuscular injections. The effect appears in general after 4 or 5 days; with bad reactivity, however, it may be belated up to about 10 days. As to the duration of effect several authors agree on a time of 6 weeks in average whereas both shorter and longer effects have been observed.

Except the sexual by-effects phenomena of incompatibility have not been recognized in any case of application.

The clinical test of the preparation has been carried out in the line of gynaecology by the

Gynaecological Infirmary of the University at Leipzig,

Director: Prof. Dr. Schröder,

Gynaecological Infirmary of the University at Berlin,

Director: Prof. Dr. Krenz;

in the line of internal medicine by the

Ind Medical Infirmary of the University at Halle,

Director: Prof. Dr. Rastbach;

in the line of surgery and urology by the

Surgical Infirmary of the University at Rostock,

Director: Prof. Dr. Karitsky.

Indications and Dosage:

25X1

Menopause as a Syndrome of the Outfall Symptoms

Whereas in former times without any objection oestrogens were frequently applied for treating the outfall symptoms in menopause recently has been pointed out more than once that the climacteric period should be considered as a biological process course of which should be controlled by carefully dosed medications of hormones only in the event of severe pathologic deficiency.

Inject one ampoule of 12 milligrams "OESTRASILBEN D", and repeat this medication, according to the gravity of the symptoms, in intervals of not less than 8 days. For younger patients with artificially induced menopause one application of 24 milligrams should be preferred. Higher dosages should be desisted from, due to the existent danger of suspended bleeding.

Upon the application of "OESTRASILBEN D" characteristic outfall symptoms such as flushes and sweats do not appear any longer, or are lessened to a minimum (2). Also the syndrome of other troubles occurring in this connection is influenced advantageously. Especially impressively the favourable effect of "OESTRASILBEN D" has turned out after severe genital operations of younger women.

Amenorrhoeas:

According to the histologic finding based on the down-stroke curettage in hormonally conditioned secondary amenorrhoea 24 to 36 milligrams of the preparation are applied. The repeated down-stroke curettage carried out after 3 weeks will prove in most cases a drastically proliferating mucosa (2). In trifling cases frequently already the sole application of "OESTRASILBEN D" in intervals of four weeks will result in a normal cycle. In tenacious cases with mostly atrophic function-lis we recommend to repeat the therapy which, if necessary, should be combined with an application of corpus luteum hormon according to the monthly cycle.

Hormonotherapy for Malign Growth:

Beside their use for treatments with palliative objective the sex hormones - and in this connection particularly the female sex hormones - have been successfully applied up to now

only in therapies for cancerous diseases within the sexual regions, and that for the inoperable cancer of the breast, the incurable genital cancer, and the prostatic cancer. According to recent opinions the body-own homosexual hormones (the oestradiol for mammary and genital carcinoma, and the testosterone for prostatic carcinoma) as well as gonadotropic hormones or, furthermore, other biocatalysts not yet known in particular and produced in the anterior lobe of the pituitary gland are deemed to encourage the canceration, too. The hormone therapy in acute cancerous diseases, therefore, is based in principle on a ligation of the secretion of pituitary hormones and, in this way, of the production of sex hormones in the reacting organ by suppression or immobilization of the pituitary gland by means of high doses of sex hormones.

As to the dosage of oestrogens in cancerous therapy recent animal-experimental examinations executed by Hohlweg and Schmauss (3) have resulted in changed points of view showing that, together with reduced hormone doses, the suppression of the pituitary gland is adequately released, and that even with constant dosage a certain habit-forming effect on the pituitary gland is achieved. The examiners therefore recommend to start the therapy with a dosis sufficient for suppressing the pituitary gland, and to increase it, whenever possible, in course of the treatment in order to prevent any deterioration by an increased activity of the pituitary gland resulting from the lessening hormone level.

a) The Prostatic Carcinoma:

Whereas upon general opinion deposit-effective follicle stimulating hormones are considered as the agent of selection for the therapy in prostatic carcinoma the experiences concerning the methodics of dosing are still prejudged in quite different manner. But there is an unanimous demand for a relatively high deposit to be set in the very beginning of the therapy - and that about 6 ccm = 36 milligrams of "OESTRA-STILBEN D". The medication of this doses should be repeated in intervals of 10 days.

Now and then a decreasing responsiveness to a hormone preparation can be observed. In such cases we recommend to continue the treatment with oestradiol preparations.

Under the effect of "OESTRASTILBEN D" a soon decrease of

metastatic pains and the inhibition of micturition as well as an amelioration of general condition can be observed. The follicle stimulating hormone therapy must not be stopped in any case.

b) Inoperable Cancer of the Breast:

The treatment of the inoperable cancer of the breast with homosexual hormones represents, according to Schmauss (5), a valuable enrichment of the hitherto known kinds of therapy. In general a favourable influence effected by follicle stimulating hormone can be expected only in cases of cancers of the breast developed during menopause. According to experiences collected the treatment with follicle stimulating hormone is exceeding the better the older the patients are, resp. the longer time has elapsed since the beginning of menopause.

The palliative treatment of the cancer of the breast with oestrogens should be used only for patients who are not less than 5 years beyond their climacteric period.

Upon clinical experiences the treatment of the inoperable cancer of the breast with oestrogens requires considerably higher doses than that of the prostatic carcinoma. The daily medication should comprise up to 30 milligrams of free oestrogens. As to TESTOSTERONE we recommend to apply twice a week 2 capsules of 40 milligrams in total. Also the treatment of the cancer of the breast with oestrogens must not be interrupted in any case.

Hypertrophy of the Prostate Gland:

Obviously there are not any relations between the hypertrophy of the prostate gland and prostatic carcinoma. Their coincidence is considered still to-day quite incidental and occurring by chance. It is considered ascertained to largest extent that androgenous hormone are acting only in sense of a tonisation of the muscular wall of the bladder not excluding, however, any cancerating effect. Oestrogens, on the contrary, are inhibiting the secretory activity of the prostate gland.

Eriessmann and Bröke (6) differentiate the symptoms of hypertrophy of the prostate gland in adenomatous prostatic nodes with predominant male sex-hormone; in such case, therefore, the therapy with oestrogens should be applied. A fibromatous node, on the contrary, results from prevailing female sex-hormone and requires a treatment with testosterone pre-

paratoma. According to extended histological examinations the adenomatous type of the disease includes 69 % of the examined cases whereas 23.5 % of them represented a mixed type so that the oestrogen therapy was nearly exclusively indicated. Ischot (7), however, reports on better successes achieved with testosterone preparations at patients in the nineties of age. The amelioration or healing is assessed on base of the dysuria, nocturia, and residual urine.

Also the adenoma of the bladder-neck has been favourably influenced by oestrogens.

According to present experiences the hypertrophy of the prostate gland required higher initial dosages than the prostatic carcinoma. We recommend to set an initial deposit of 60 milligrams, i.e. 3 ampoules per 2 ccms with 12 milligrams of Oestrastilen D each, and to apply once a week 12 milligrams for a period of 8 weeks. During the treatment regular determinations of serum phosphatase should be made. If in tenacious cases the finished treatment results in a negative finding we advise to stop the treatment with this therapy.

Disturbed Passage of Blood:

The properties of the follicle stimulating hormone encouraging the passage of blood are making the "OESTRASTILEN D" suitable also to most extended applications for organic and functional disturbances of passage of the blood as well as for circulatory and metabolic disturbances caused by the climacteric process.

As to the dosage we recommend the injection of firstly 1 ampoule of 12 milligrams of "OESTRASTILEN D". According to the effect on the disease repeated medications of equal doses in intervals of about 10 days are indicated.

To women of generative age, if possible, only one injection of 12 milligrams should be applied within one cycle, and that on the fourth day after the beginning of the menstruation.

Sexual phenomena (reaction of mammary glands and disturbances of generative capacity) appearing at male patients under the effect of "OESTRASTILEN D" are improved again within a short time after the therapy has been finished.

Gastric and Duodenal Ulcer:

25X1

In spite of the recent but nevertheless still uncertain methods of ulcer therapy the simultaneous application of follicle stimulating hormones together with usual dietetical precautions and practices are highly esteemed now as before. Whereas the achievement of objective healing successes is still discussed the palliative value of the application of follicle stimulating hormones is hardly contested. According to present experiences the application of deposit-effective oestrogens represents without any doubt an improvement of the hitherto known therapeutical possibilities.

Dosage:

Start with 2 times 2 ccms of "OESTRASILBEN D" within the first week with subsequently decreasing doses.

Packings for Sale:

Original packing: 2 ampoules of 2 ccms with 12 milligrams of biocatalyst each.

Clinical packing: 12 ampoules of 2 ccms with 12 milligrams of biocatalyst each.

Literature:

- (1) Eldem: I.am.med.Assoc. 140, 1214 (1949) 53, 263 (1947)
- (2) Winter: Dtsch.Ges.Wesen 25, 784 (1952)
- (3) Schmauss: Arch.Geschwulstforsch. 3, 201 (1954)
- (4) Reinhold: Dtsch.med.wchr. 23, 770 (1951)
- (5) Schmauss: Z.ärztl.Fortbildung 7/8, 176 (1952)
- (6) Griegemann & Druke: Vortrag auf der 29.Tagung der Deutschen Gesellschaft für Gynäkologie in München, Oktober 1952
- (7) Tschet: J.Ur.France 58, 105 (1952)

ERD 15/11/43

- 1 -

71112X 13

25X1

25X1

V i t a m i n K " P h a r m a "

(2-methyl-1·4-naphthochinon-sodium bisulphite)

Ph
J

VBB PHARMACEUTISCHES WERK JOHANNISTHAL

BERLIN-JOHANNISTHAL - AM FLUGPLATZ 6

25X1

118 132

25X1

VITAMIN K "PHARMA"(2-methyl-1·4-naphthochinon-sodium bisulphite)

In 1930 there was observed by Dam and his assistants that new-born chicken, when provided with fodder free from lipid, suffered from cutaneous and mucosal haemorrhages, and it was found that such haemorrhages were caused by the lack of a vitamin occurring in green vegetable parts and unknown up to that time. This vitamin was called "anti-haemorrhagic vitamin" or "vitamin K". Later on Karrer and Doisy managed to educe the vitamin K₁ in pure condition and to determine it, upon further experiments, as a derivate of 1·4-naphthochinon.

To-day two natural K-vitamines are distinguished:

K₁ is of vegetable origine

(contained in spinach, cabbage, lucerne, tomato, Alfalfa-hay),

K₂ is of animal origine

(isolated from rotting fish-flour).

Both are fat-soluble and resorbable only in presence of gallic acids. Whereas the vitamin K₂ has only an efficiency of about 60 % of that of vitamin K₁, a simple derivate of the 1·4-naphthochinon, i.e. the

2-methyl-1·4-naphthochinon

in respect to its therapeutical effect essentially surpasses the vitamin K₁.

Properties:

The 2-methyl-1·4-naphthochinon-sodium bisulphite -

VITAMIN K "PHARMA"

produced in our works is an especially high-valued therapeutical product of water-soluble condition which, in contradistinction to natural vitamines K₁ and K₂, is resorbed by the intestine even in absence of bile, and does not entail any intoxication even in the event of considerable overdosing.

Whereas the therapy was interested up to now substantially in the antihæmorrhagic effect of the vitamin K nowadays also two recently discovered and still nearly unknown properties of the vitamin K are gaining considerable importance, and that its antibacterial and anticarcinogenic efficiency.

Effect:

In case of lack of vitamin K the clotting power of the

blood is prolonged with the lessening level of prothrombin. The clotting process may be outlined as follows:

1. Activation of the ferment prothrombin by vitamin K which is necessary for the formation of prothrombin.
2. Conversion of the activated prothrombin, in presence of Calcium and the ferment thrombokinase, into thrombin.
3. Formation of fibrin, under the effect of thrombin, from the colloiddally dissolved albuminous body present in the plasma.

The lack of vitamin K may be caused

1. by disturbed formation of prothrombin, due to damages the liver-cells are afflicted with,
2. by physiological hypoprothrombinemia of new-born babies during their first week of age, due to a still insufficient function of the liver resulting from a probably present impermeability of the placenta for vitamin K as well as from the absent bacterial flora of the intestine which is the main source of vitamin K,
3. by restricted resorption of fats and, in this way, also of the fat-soluble vitamin K, due to blocked bile-ducts as resulting e.g. from gallstones and tumours.

As to the anticarious and antibacterial properties

U.S. Foodick and other authors found in course of their work:

1. In saliva and the mouth respectively sugar is easily converted into acid products decalcifying the teeth and favouring the occurrence of caries.
2. Vitamin K, according to Foodick a ferment suppressing matter, prevents the saliva to decompose sugar into acid products, thus excluding their injurious effect on the teeth and taking care of a prophylactic anticarious efficiency.

The caries, moreover, can be influenced by vitamin K from the bacterial part, too.

3. Vitamin K inhibits in and even outside the mouth the formation of certain bacteria and fungi.

Indications:

In case of lack of vitamin K the indications result from the given causes whereas Gentzkens's examinations of new-born babies in respect to the morbus haemorrhagicus neonatorum and physiologic jaundice of the new-born child are of special

of the liver is substantially strengthened if a vitamin K 25X1 refractory reduction of the level of prothrombin is found. In the event of the vitamin K refractory hypoprothrombinemia lessening below 30 % the suspicion of an acute dystrophy of the liver, at further reduction that of a coma hepaticum would be given.

The following procedure should be adhered to: discharge of 5, resp. 10 ccm oxalic blood in the morning in jejune condition (i.e. 1 ccm of 1.34 % sodium oxalate and 9 ccm of blood), quantitative determination of the prothrombin according to Quick. Subsequently to the discharge of blood intramuscular injection of 30 mgs of vitamin K, after 24 hours repeated determination of the level of prothrombin.

Dosage:

The therapeutic dosage ranges normally between 10 and 20 milligrams per day, and that for 1 to 3 days once or twice a day one ampoule injected intramuscularly, intravenously or subcutaneously, or for 8 days thrice a day 1 to 2 sugared pills or evtl. combined parenteral and oral application. In acute cases the dosage may be increased up to 50 to 100 milligrams (to be applied by slow, intravenous injections) since light injuries of animals have not been observed unless upon doses which are never applied in clinical practice (e.g. 10 milligrams per kilogram body-weight resulting in light vomiting of dogs).

Packings for Sale:

Boxes of 5 ampoules of 1 ml each = 10 milligrams
Boxes of 25 ampoules of 1 ml = 10 milligrams each
Boxes of 5 ampoules of 2 ml each = 100 milligrams
Tubes of 20 sugared pills of 10 milligrams each
Glass of 250 sugared pills of 10 milligrams each.

Literature:

1. Tanner and Luter, Schweiz.Med. Schr. 74, 552 (1943)
2. Koller, F. and A. Pedrazzini, Schweiz.Med. Schr. 911 (1947)
3. Breitmaier, Med.Klinik 23/561-66 (1946)
4. Ludwig von Varga, Arztl.Forschung 151/57 (1948)
5. Pam, Nature (London) 133-139 (1934)
6. Pam, Zeitschrift für Vitaminforschung 9-71 (1939)
7. Gaethgens, "Das Vitamin K in der Physiologie und Pathologie der Frau und der Neugeborenen",
Gg.v.Thieme Verlag, Leipzig, (1946)

- 6 -

8. Geethgens, Arztl.Forschung 255/264 (1948)
9. Koller, "Das Vitamin K und seine klinische Bedeutung",
Gg. Thieme Verlag, Leipzig (1941)
10. Schüller, Arztliche Wochenschr. 55-56 (1948)
11. R.R. Gordon, The Lancet 6556 : 692 (1949)
12. Dr. A.Banos, Arch.Kinderkh. 133 (1946)
13. Cvilichovskaja, E.E.Suvalova, T.E.Chelabuzarj, A.M.
Timofejewa, Klin.Medizin 4-5/XXIV, 59-65 (1946)
14. F. Hauser, Annales Paediatrici, Vol.168, No.I (1947)
15. A.Hermann Müller, Z.f.d.ges.Inn.Med. 9/10 S, 284/88 (1947)
16. P. Kallos, Gastroenterologica 3 (1946)
17. H. Uhse, "Das Vitamin K in der Behandlung des Keuchhustens"
Das Deutsche Gesundheitswesen No.19 (1953)
18. "Die Vitamine" (Schweiz) No.3 (1952): "Zwei noch wenig
bekannte Eigenschaften des Vitamins K"
19. H. Uhse: Das Vitamin K in der Behandlung des Keuchhustens.
Neue Erkenntnisse der Vitamin K - Wirkungen.
Das Deutsche Gesundheitswesen No.27 (1954)

Export Informations may be obtained from:

Deutscher Innen- und Außenhandel Chemie,
Berlin C 2, Schioklerstraße 5-7

Olypon AFE

as auxiliary colouring matter for sulphur dyeing (Textiles)

Introduction

25X1

The sulphur dyes being mostly insoluble in water are for dyeing purposes made soluble by reducing them. The reduction of the dye stuff is carried out by means of sulphuret of sodium which simultaneously serves as a solvent for the reduced dye stuff. The required quantity of soda increases the alkalinity in order to prevent any decomposition of the sulphuret of sodium. The application of the dissolved dye stuff to the fibre is improved by the addition of Glauber's salt. The required quantities of sulphuret of sodium, soda, and Glauber's salt should be taken from the instructions issued by the dye factories.

Dissolution of the Sulphur Dye:

The dye stuff is made doughy in hot water by adding the appropriate quantity of sulphuret of sodium, and subsequently boiled up. For improving the doughing and dissolving of the dye stuff Olypon AFE (see fig.2) is added.

For one litre normally 0.5 to 1 gram of Lamapon AFE are used.

Properties of the Olypon AFE (Dye.....)

Olypon AFE is sold in shape of a brown, water-soluble oil. In chemical respect it is a condensate of fatty acid. Owing to its excellent qualities it is one of the best textile auxiliaries of modern times. Beside its extraordinary resistivity against hardeners it owns a good capability of cleaning, soaking, dispersing, and foaming, and it is suitable to any neutral, alkaline, and acid colour dyes. Lamapon AFE may be mixed up with water in any ratio, and it is perfectly fast to boiling, even when boiled under pressure.

10 ccm NaOH 26° B_é
in 1 ltr H₂O 15° DH

10 ccm NaOH 26° B_é
2 gr of Olypon AFE
in 1 ltr. H₂O 15 DH

Precipitationno Precipitation

Figure No.1

Olypon AFE is mainly used for sulphur and naphthol dyeing.

On request special instructions are placed at your disposal, or the procedure is demonstrated by our technicians. Normally out of the required dose of Olypon AFE one half is taken for improving the dissolution of the dye stuff whereas the other half is added to the dye bath prior to the insertion of other additions. This is important particularly where hard industrial water is used. Upon addition of Olypon AFE no precipitations will occur in hard water (see fig. 1).

Filter Test

20 ccm immediate dark blue dye RL plv. (1:100), resp. with 10 ccm Olypon AFE (1:10)

25 ccm sulphuret of sodium (1:10)

100 ccm boiling H₂O

520 ccm boiling H₂O

10 ccm Olypon AFE (1:10)

25 ccm sulphuret of sodium (1:10)

Figure No. 2

Test with Olypon AFE

In order to prevent any bronzing we recommend to treat the sulphur-dyed material with 0.5 to 1 g sulphuret of sodium) per 1 g Olypon AFE) ltr. for 10 minutes at 50 °C, and subsequently to scavenge and oxidize it carefully.

Olypon AFE for Naphthol Dyeing

General:

The naphthol AS dyes are insoluble dye stuffs. The dyeing procedure includes two operations, and, that is:

- a) grounding
- b) developing.

The naphthol is dissolved with soda lye to naphtholate which is used for grounding the fibre material. After grounding the surplus of the naphtholate solution must be removed from the fibres. Subsequently the dye stuff is evolved in a solution of diazonium salt, and that according to the following scheme:

25X1

The Dissolution

The naphthols can be dissolved according to two procedures, and that:

- 1) by hot dissolution, and
- 2) by cold dissolution.

As to 1): The naphthol is well doughed with Olypon AFE, then the corresponding dose of soda lye of 38°Bé is added, and subsequently hot water is added in exact adherence to the prescription. When doing so take care of obtaining a clear solution. Otherwise we recommend to boil up shortly the solution. According to the prescriptions now the required quantities of cold water are added as well as 33 per cent formaldehyde, and then the required volume is filled up.

As to 2): The naphthol is dissolved according to prescription paying attention only to the Olypon AFE being added to the grounding bath. 1 to 2 grams of Olypon AFE per litre will suffice.

Filter Test

10 gr naphthol AS
- Olypon AFE
15 ccm NaOH 38°Bé
150 ccm H₂O hot
150 ccm H₂O cold
10 ccm formaline
1000 ccm to be filled up

Developed with:

50 ccm Ehtrot-salt TR
(1:100)

20 gr naphthol AS
3 gr Olypon AFE
15 ccm NaOH 26°Bé
150 ccm H₂O hot
150 ccm H₂O cold
10 ccm formaline
1000 ccm to be filled up

Developed with:

50 ccm Ehtrot-salt TR
(1:100)

Figure No.3

without Olypon AFE

with Olypon AFE

General:

It is of special importance for naphthol dyeing to keep the baths of the dissolved naphthol in solution as long as possible, and that both in diluted and in concentrated brine (see fig.4).

It is very important, furthermore, to add to the grounding bath a first-class soaking agent, as to attain a good grounding effect.

SECRET

Both requirements for naphthol dyeing are complied with by
Olypon AFE.

Olypon AFE is a high-valued protective colloids of high
masking effect. Even in hard water the naphthol solutions
remain clear. Attention should be paid only to the Olypon AFE
(1 g/ltr.) being added to the grounding bath before any
other additions are added.

10 gs naphthol AB
21 ccm NaOH 26°Bé
150 ccm hot H₂O
150 ccm cold H₂O
10 ccm formaline

filled up to:
1000 ccm H₂O 15 DH

after short time
precipitation

10 gs naphthol AB
10 ccm Olypon AFE (30:70)
21 ccm NaOH 26°Bé
150 ccm hot H₂O
150 ccm cold H₂O
10 ccm formaline

filled up to:
1000 ccm H₂O 15 DH
+ 1 ccm Olypon AFE
(30:70)
+ 1 ccm NaOH 26°Bé

the naphtholate solution
remains clear.

Figure No.4

Indanthrene Dyeing

As everybody knows indanthrene dye stuffs cannot be dyed
unless at 60°C. Practical experiences have shown difficulties
in the dyeing of perlon materials with indanthrene dye stuffs:
for obtaining a certain shade it is necessary to increase the
temperature up to 90°C.

It is not unknown that the bath tends to break down at higher
temperatures. For maintaining the bath considerable quantities
of hydrosulfite are required. Upon addition of Olypon AFE the
bath remains unchanged in spite of the increased temperature,
and that without addition of larger quantities of hydrosulfite.
In other words: by the addition of Olypon AFE we are in a
position to dye also indanthrenes at 90°C without extra
consumption of hydrosulfite.

without prejudice!

VEB Chemische Fabrik Grünau
Berlin-Grünau
Regattastrasse 35
Tel. 64 40 61

Composition of the Preparations Listed in the
Veterinary Drug Catalogue 1956

25X1

Arsenic Cures for Horses

	20 %	30 %	50 %
Arsenious acid	20 %	30 %	50 %
Filling agent to 100 %			

Ointment B F 2

Ointment base	85.0 %
Benzoic acid	
Turpentine-oil	
Glycerine	
Oxide of zinc	

The biocatalysts are composed according to special prescription.

Powder for Glanders

Gentian-root
Fennel-seed
Juniper-berries
Fenugreek seed
Glauber's salts
Chloride of soda
Stibium sulphuratum nigrum

The composition is made according to special prescription.

Ointment for Inflammatory Swellings

Ointment base	80.0 %
Gray quicksilver salve	
Camphor	
Cade-oil	

The biocatalysts are composed according to special prescription.

Emucation

Emulsion base 88.0 %

Camphor

Turpentine-oil

Oil of mustard

Solution of ammonia

The biocatalysts are composed according to special prescription.

Udder Ointment

Ointment base

78.0 %

Aluminium acetate

Turpentine-oil

The biocatalysts are composed according to special prescription.

Palkitol-pills for Horned Cattle and Sheep

The biocatalysts are composed according to special prescription, and that on base of hexa-ethyl-chloride.

Tetter Ointment

Ointment base

87.9 %

Solution of formaldehyde

Lubricant

Celline

Sterilizer

The components are dosed according to special prescription.

Hippascan

Arsenious acid

Carbonate of potash

Sterilizer

Solvent

The components are dosed according to special prescription.

Cod-liver Ointment

25X1

Ointment base 80.0 %
Cod-liver-oil

Cod-liver Zincointment

Ointment base 63.0 %
Cod-liver-oil
Oxide of zinc
Sterilizer

The biocatalysts are composed according to special prescription.

Milking-grease

Vaseline
Glycerine
Sterilizer

The components are dosed according to special prescription.

Ear-oil for Small Cattle

Hexantriol
Balsam Peru

The components are dosed according to special prescription.

Panaritan

Sulphate of zinc
Sulphate of copper
Alum
Tannic acid
Coal-preparations for absorption

The components are dosed according to special prescription.

Suascan

Arsenious acid
Carbonate of potash
Sterilizer
Solvent

25X1

85.0 %

The biocatalysts are composed according to special prescription.

Sulphonamide Dusting Powder 10 %, 20 %, 50 %

Powder base 90.0 %
p-dimethylsulphonamide

Tannoform Dusting Powder

Powder base 80.0 %
Tannoform

Tannosal

Powder base 66.0 %
Oak-bark
Tannic acid
Salicylic acid
Tannalbin
Falkenauer del Berlin, Dalgower StraÙe 18-22
Falkenauer del Berlin, Dalgower StraÙe 18-22
The biocatalysts are composed according to special prescription.

Tinct. Stomachica Amara

Tincture of worm-wood
Tincture of gentian
Tincture of scorus

The components are dosed according to special prescription.

Camphor Ointment 10 %, 20 %

Ointment base 90.0 %
Camphor

- 8 - - 4 -

Emulsion "PL"

Emulsion base
Glycerine
Perugene

Emulsion base
85.0 %
Glycerine
Perugene

The biocatalysts are composed according to special prescription.

2 % Pyoctanine Solution

Pyoctanine 3 %
Solvent

Pyoctanine
Solvent
Pyoctanine
Solvent

Rivanol Ointment for the Eyes with Pantocain

Eye-ointment base
Rivanol
Pantocain

99.5 %

The biocatalysts are composed according to special prescription.

Rivanol Dusting Powder

Powder base
Rivanol

95.0 %

Rumivet Simple

Tincture of worm-wood
Tincture of hellebore
Tincture of scorus
Hydrochloric acid

The components are dosed according to special prescription.

Rumivet Forte

Chlorate of barium
Tincture of hellebore
Hydrochloric acid

The components are dosed according to special prescription.

- 5 -

- 5 -

25X1

Suasean

Arsenious acid
Carbonate of potash
Sterilizer
Solvent 95.0 %

The biocatalysts are composed according to special prescription.

Sulphonamide Dusting Powder 10 % 20 % 50 %

Powder base 90.0 %
p-aminophenylsulphonamide

Tannoform Dusting Powder

Powder base 80.0 %
Tannoform

Tannosal

Powder base 66.0 %

Oak-bark

Tannic acid

Salicylic acid

Tannalbin

Falkensee bei Berlin, Dalgower Strasse 18-22

The biocatalysts are composed according to special prescription.

Tinct. Stomachica Amara

Tincture of worm-wood

Tincture of gentian

Tincture of scorus

The components are dosed according to special prescription.

Camphor Ointment 10 % 20 %

Ointment base 90.0 %
Camphor

- 5 -

- 6 -

Camphor Ointment and Ichthyol Ointment 1 : 1

Ointment base 90.0 %
 Ichthyols
 Camphors

Ichthyol Ointment 10 % 20 % 50 %

Ointment base 90.0 %
 Ichthyols

Ointment of Salicylic Soap with Camphor and Iodine

Ointment base 50.0 %
 Salicylic acid
 Methylum salicylicum
 Camphor
 Iodine

The biocatalysts are composed according to special prescription.

VEB (K) Chemische Fabrik Falkensee,
Falkensee bei Berlin, Dallgower Straße 16-22
 (Betriebsnummer: 04/1462)

Deutscher Text
Seite:

Umschlag I

OPF - VEB (K) Chemische Fabrik Falkensee

25X1

Falkensee bei Berlin, Dallgower Str. 16-22 • Phone:
Falkensee 3027

Catalogue of Veterinary Drugs

January, 1956

Umschlag II By this catalogue we beg to give you a summary on our veterinary drugs produced at present time (January 1, 1956). -

The veterinary drugs produced in our works are sold to veterinarians and drugstores only. In special cases, however, and upon veterinary prescription direct supplies to final users are possible.

- 1 - (- Siehe Umschlagseite I ! -)

Designation	Indication	Packing
<u>Arsenic Cures</u> <u>for Horses</u>		35 packed powder doses of 1 g each, for one treatment of 5 weeks
<u>B.T.Z.-Ointment A</u>	For the treatment of wounds as well as itching and antiphlo- gistic skin-diseases, eczemata and other cutaneous damages	Corrosin box of 100 grams
<u>Powder for Horse</u>	For diseases of the larger air-passages as well as for strangles	Packing of 250 g
<u>Ointment for In- flammatory Swellings</u>	Resolvent	Box of 100 grams
<u>Embrocation A</u>	Antiphlogistic, anti- neuralgic for absorbing massages irritating the skin in case of rheumatic diseases of any kind, arthritis, phlegmons, etc.	Glass bottles of 200 ml each

Deutscher Text

Seite:

- 2 -

25X1

- 3 -

<u>Designation</u>	<u>Indication</u>	<u>Packing</u>
<u>Udder Ointment E</u>	For phlegmons and per- sachymatous inflammat- ions of the udder, for epithelial diseases as well as inflammatory eczemata	Porcelain bottle of 100 grams
<u>Falkitol-pills A</u>	For combating against the fluke-worm disease of horned cattle and sheep	for horned cattle: (10g) box of 40 pos for sheep: (8 g) box of 14 pos
<u>Tetter Ointment</u>		Box of 100 grams
<u>Lubricant</u>	Non-greasing arm lubric- ant, disinfecting, wash- able. For rectal and vaginal obstetrics, suitable to being used as substitute of amniotic liquor	Bottle of 1000 ml, balloon of 25 lgs
<u>Hippasean A Rp</u>	Reliable worm lubricant for ascarides of horses and foals, also acting against strongylides	Bottles of 200 ml each
<u>Cod-liver Ointment A</u>	As vulnerary and curing ointment especially in- dicated for bad-healing ulcers, fistulae and burns as well as for the treatment of eczemata	Porcelain box of 100 grams
<u>Cod-liver Zinc- ointment A</u>	For erosions, wounds, penaritis, and as lub- ricant and protective ointment for obstetrics and for rectal examinations	Porcelain box of 100 grams
<u>Milking-grease</u>	For softening and dis- infecting the milker's hands and the teats	Boxes of 500 and 1000 grams

- 4 -

- 3 -

Deutscher Text

Seite:

- 3 -

- 4 -

(Forts.)

Designation	Indication	Packing
<u>Ear-oil for Small Cattle</u>	For otitis externa ceruminosa, especially otitis externa parasitaria of dogs, cats, and rabbits	Bottles of 30 ml each
<u>Panaritan A Rp</u>	Desiccative, leniently cauterizing dusting powder for panaritria, wart malanders, malanders, laming due to mustiness as well as for after-treatment of cancer of the hooves	Parcel of 100 gs
<u>PL-emulsion A</u>	For promoting the granulation and epithilization process, for use as hair-restorer in alopecia as well as for heavily itching skin-diseases, particularly with small cattle practice	Bottle of 100 ml
<u>Pix Liquida</u>	Antiseptic	Balloon box of 1 kg
<u>2 Pyoctanin Solution</u>	Sterilizing agent for chafed wounds	Bottle of 100 ml
<u>Bivanol Dusting Powder</u>	Antiseptic powder	Dusting box of 50 grams
<u>Rumivet A Rp</u>	For acute and chronic gastric and intestinal catarrhs, stimulating contraction and peristalsis, promoting ruminating	Glass bottle of 100 millilitres
<u>Rivanol Ointment for the Eyes with Pantocain A Rp</u>	Alleviating and anti-itching ointment for the eyes in conjunctivitis, keratitis, blepharitis	Porcelain box of 10 grams

- 5 -

- 4 -

25X1

Deutscher Text

Seite:

- 4 -

- 6 -

<u>Designation</u>	<u>Indication</u>	<u>Packing</u>
<u>Rumivet Forte A Rp</u>	Strong Rumination promoting agent similar to Rumivet	Bottle of 100 ml
<u>Suascan A Rp</u>	Vermicide for pigs and young pigs affected by ascarides, also used for resolving arsenic cures for swines, sheep, and she-goats	Bottle of 100 ml
<u>Sulphonamide Dusting Powder 10, 20, and 50 % A Rp</u>	For poisoned wounds, malign oedema, gas-gangrene, burns, frost-bites, otitis, cancer of hooves, etc.	Dusting box of 100 grams
<u>Tannoform Dusting Powder A</u>	For wounds of most different kind as well as drying antiseptic for wet malanders	Dusting box of 100 grams
<u>Tannosal A</u>	Astringent medicine and intestinal disinfective especially for diarrhoea, dysentery of calves, tympany	O.P. 100 grams
<u>Tinct. Stomachica Amora A</u>	For anorexia of beasts of any kind, also as roborantien tonic in debility, dyspepsia, etc.	Bottle of 100
<u>Camphor Ointment 10 and 20 % A</u>	For provoking local hyperaemia in case of phlegmons, inflammations of udder and lymphatic glands, suppurative tendovaginitis, bad-granulating wounds, ulcers, and fistulae	Box of 100 grams

- 7 -

- 5 -

Deutscher Text

- 5 -

Seite:

- 7 -

(Forts.)

Designation	Indication	Packing
<u>Ungt. Camph. et Ungt. Ichthyoli 1:1 A</u>	Antiseptic for wounds and hurts	Porcelain bottle of 100 grams
<u>Ungt. Ichthyoli 10, 20, and 50 A</u>	Antiseptic agent for wounds and hurts	Porcelain bottle of 100 grams
<u>Ungt. Sapo Salic. cum Camph. et Iod. A</u>	Laming, Rheuma	Porcelain bottle of 100 grams
<u>White Oil Pharm.</u>		Bottles of 1 kg. and large parcels

- 8 -

CONDITIONS FOR SALE AND DELIVERYOffers :

Our offers are not obligatory. Mutual, contracted obligations are not binding unless upon our confirmation of order in writing.

Delivery :

The buyer bears any risk of transportation, even in the event of agreed free delivery. In case of force majeure we are entitled to postpone the delivery for the time of such condition or to withdraw from the contract in total or partially. Claims are considered only when notified within 8 days following the receipt of the goods.

Lent Packings :

The lent packings should be carefully treated and returned, in accordance to Official Gazette No. 125 dated 28/11/1953,
a) from large industrial works within 45 days,
b) from any other enterprise within 30 days.

Property Reserved :

Supplied goods incl. packing remain in our property until complete payment is effected.

Payment :

Terms of payment in accordance to the 6th ordinance to the Enactment Concerning the Financial Economy of People's-own Enterprises. The invoiced amount should be paid not later than 15 days from the date of the invoice, and without any reduction. In the event of delayed payment, the buyer has to pay for interests on account of deferred payment which amount to 8 %

- 6 -

25X1

Deutscher Text

- 6 -

Seite:

- 8 -

(Forts.) p.s. of the invoiced sum.

Settling Place and Competence of Court:

The settling place is our factory store in Falkensee.

The competent court is that which is competent for Nauen.

VEB (K) CHEMISCHE FABRIK FALKENSEE

Umschlag III Out of our manufacturing program we recommend to use
the highly effective fine-disinfectant

B A C T O S E P T

Z

CONTAINING THE BIOCATALYST Z 2

bactericide

fungicide

GFF

25X1

Sanitized Copy Approved for Release 2010/02/16 : CIA-RDP80T00246A032301010001-0

Page Denied

25X1

Sanitized Copy Approved for Release 2010/02/16 : CIA-RDP80T00246A032301010001-0